SuperworthBridgeBio Pharma EPS BBIO
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$3.57
- Latest quarter, Q2 FY26
- −$0.78
- Fiscal year 2025
- −$3.78
BridgeBio Pharma's earnings per share was −$3.57 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.78.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.78 | n/a |
| FY2024 | −$2.85 | n/a |
| FY2023 | −$3.94 | n/a |
| FY2022 | −$3.27 | n/a |
| FY2021 | −$3.91 | n/a |
| FY2020 | −$3.80 | n/a |
| FY2019 | −$2.50 | n/a |
| FY2018 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.78 | n/a | −$3.57 | |
| Q1 FY26 | −$0.84 | n/a | −$3.74 | |
| Q4 FY25 | −$1.00 | n/a | −$3.78 | |
| Q3 FY25 | −$0.95 | n/a | −$4.18 | |
| Q2 FY25 | −$0.95 | n/a | −$4.09 | |
| Q1 FY25 | −$0.88 | n/a | −$3.53 | |
| Q4 FY24 | −$1.40 | n/a | −$2.85 | |
| Q3 FY24 | −$0.86 | n/a | −$2.41 | |
| Q2 FY24 | −$0.39 | n/a | −$2.63 | |
| Q1 FY24 | −$0.20 | n/a | −$3.22 | |
| Q4 FY23 | −$0.96 | n/a | −$3.94 | |
| Q3 FY23 | −$1.08 | n/a | −$3.90 |
Against its peers
Companies in Drug Manufacturers - General nearest BridgeBio Pharma's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BBIOBridgeBio Pharma | −$3.57 | |
| JAZZJazz Pharmaceuticals | $14.62 | |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| BIIBBiogen | $5.65 | −46% a year |
| Peer median | $1.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on BridgeBio Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.